ArticlePloS one2025
An exploratory study on predicting HER2-positive expression status of breast cancer using ultrasound radiomics combined with machine learning models.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the feasibility and potential value of predictive models for human epidermal growth factor receptor 2 (HER2)-positive status in breast cancer (BC) based on radiomics features from conventional ultrasound images and machine learning models.
methodsUltrasound images of 437 patients with surgically and pathologically confirmed BC were retrospectively analyzed, including 144 HER2-positive and 293 HER2-negative cases, which were used as a training and validation dataset. Key features highly correlated with HER2-positive status were identified and selected using the least absolute shrinkage and selection operator (LASSO), t-test, and principal component analysis (PCA). After the selection of relevant features, the dataset was randomly split into five equal parts for five-fold cross-validation to identify the optimal machine learning method and hyperparameters. A predictive model was then developed based on ultrasound imaging and radiomics features. After feature selection and model development, an additional cohort of 88 patients from other hospitals was utilized as an external validation dataset. The model's internal validation performance was assessed through receiver operating characteristic (ROC) curve analysis, and metrics including area under the curve (AUC), sensitivity, and specificity were calculated. The generalizability of the model was further evaluated using the external validation.
resultsFive radiomics features were found to correlate with HER2-positive status in BC and used for model construction. Among the machine learning models generated, the best predictive model achieved area under the ROC curve values of 0.893 (95% confidence interval [CI], 0.860-0.920) in the training and validation dataset and 0.854 (95% CI, 0.775-0.927) in the external validation dataset.
conclusionMachine learning models based on ultrasound radiomics features have potential clinical value for predicting HER2-positive status in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.